AI summary · may contain errors
Teclistamab treatment in 10 severe, treatment-refractory systemic sclerosis patients is linked to near-complete elimination of bone marrow and skin B-cells and plasma cells, with a median 70.6% antitopoisomerase antibody titre reduction.
- Open access
- 8 cites
